Background: Low awareness of chronic kidney disease (CKD) may reflect uncertainty about the accuracy or significance of a CKD diagnosis in individuals otherwise perceived to be low risk. Whether reclassification of CKD severity using the CKD Epidemiology Collaboration (CKD-EPI) equation to estimate glomerular filtration rate (GFR) modifies estimates of CKD awareness is unknown.
C
hronic kidney disease (CKD) is common in US adults, and it contributes to increased risks of death, end-stage renal disease, and cardiovascular events. 1, 2 Although awareness of CKD has improved modestly over time, it remains low. For example, in the 2000-2004 National Health and Nutrition Examination Survey (NHANES), 6% of individuals with CKD were aware of the condition. 3 In those with stage 4 CKD, less than half were aware, and in those with stage 3 CKD, less than 15% were aware. 3 Early detection and treatment of CKD may slow progression, prevent complications, and increase preparedness for end-stage renal disease. Thus, improving CKD awareness in patients and providers is a key step toward improving CKD care.
Low CKD awareness may reflect poor provider recognition and communication of CKD and uncertainty about the accuracy of a CKD diagnosis in certain individuals. The 4-variable Modification of Diet in Renal Disease (MDRD) Study equation used to estimate glomerular filtration rate (GFR) has gained broad acceptance in clinical care, yet controversy remains about the implications of its widespread use.
In particular, because the MDRD Study equation systematically underestimates GFR, especially in individuals with GFR Ͼ60 mL/min/1.73 m 2 , it may lead to false-positive diagnoses of CKD.
report CKD diagnoses to patients they consider at low risk of progression or other complications.
The newly developed CKD Epidemiology Collaboration (CKD-EPI) equation is reported to have greater precision and less bias for estimating GFR. 7, 8 Its application has led to a downwardly revised estimated US prevalence of CKD, attributable primarily to a lower prevalence of stage 3 CKD (eGFR, 30-59 mL/min/1.73 m 2 ). 7 Preliminary reports suggest that the CKD-EPI equation also may be more accurate for mortality risk prediction than the MDRD Study equation. 9, 10 We used data collected as part of the Kidney Early Evaluation Program (KEEP), a communitybased convenience health screening sample, to compare estimates of CKD awareness using the CKD-EPI and MDRD Study equations. We hypothesized that the high prevalence of CKD unawareness would be attenuated by reclassification of CKD severity using CKD-EPI estimates of GFR.
METHODS

Study Population
KEEP is a free community-based voluntary screening program launched in August 2000, designed to identify individuals at increased risk of kidney disease and encourage follow-up care.
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KEEP screenings are conducted in urban and rural locations throughout the United States through each state's National Kidney Foundation affiliate. In this study, we included eligible KEEP participants screened from August 2000 through December 2009 (n ϭ 123,704) aged at least 18 years with a diagnosis of CKD based on National Kidney Foundation guidelines using the MDRD Study equation to estimate GFR (n ϭ 28,109). From this sample, we excluded individuals receiving maintenance dialysis or with a previous kidney transplant, leaving 27,987 individuals in the analytic cohort. We further excluded individuals with missing values for CKD awareness and other covariates, resulting in a final sample size of 26,213.
KEEP Screening Procedures
During KEEP screening, participants complete a questionnaire to assess demographic characteristics, personal and family medical history, and health behaviors. Blood pressure, height, and weight nonfasting glucose values Ն200 mg/dL. Hypertension was defined as self-report, use of medications for hypertension, systolic blood pressure Ն130 mm Hg, or diastolic blood pressure Ն80 mm Hg. Cardiovascular disease was defined as self-report of heart angioplasty, heart bypass surgery, heart attack, heart failure, abnormal heart rhythm, stroke, or peripheral vascular disease (peripheral vascular disease information was collected until only May 2005).
Statistical Analysis
Participant baseline characteristics and CKD awareness are described by CKD stage and eGFR equation using proportions. We used logistic regression, expressed as odds ratio (OR) and 95% confidence interval (CI), to describe the association of CKD stage and other clinical characteristics with CKD awareness. Separate models were constructed using eGFR MDRD and eGFR CKD-EPI to categorize CKD stage. Adjusted models accounted for age, sex, race, education, and diabetes plus all other variables significant at the P Ͻ 0.1 level in unadjusted analyses. To determine the relation between reclassification of CKD severity using eGFR CKD-EPI and CKD awareness, we first determined the reclassification rate in unaware and aware participants. Next, we classified participants into 3 categories as follows: unchanged CKD stage using eGFR CKD-EPI versus eGFR MDRD , less advanced CKD stage using eGFR CKD-EPI versus eGFR MDRD , and more advanced CKD stage using eGFR CKD-EPI versus eGFR MDRD . These categories were used to determine the unadjusted and multivariable-adjusted associations between CKD reclassification and awareness. We further stratified analyses by CKD stage to assess whether findings were consistent. Analyses were conducted using SAS, version 9.2 (www.sas.com).
RESULTS
Using eGFR MDRD , 26,213 participants were classified with CKD: 8,134 (31%) with stages 1-2 and 18,079 (69%) with stages 3-5 ( Table 1) . Using eGFR CKD-EPI , 23,572 participants were classified with CKD: 8,421 (32%) with stages 1-2 and 15,151 (58%) with stages 3-5. Thus, 2,641 participants (10%) were classified with CKD using eGFR MDRD , but not eGFR CKD-EPI . Of participants with CKD using eGFR MDRD , 9.5% were aware of CKD; 4.9%, 6.3%, 9.2%, 41.9%, and 59.2% with stages 1-5, respectively, were aware (Fig 1) . Of participants with CKD using eGFR CKD-EPI , 10.0% were aware of CKD; 5.1%, 6.6%, 10.0%, 39.3%, and 59.4% with stages 1-5, respectively, were aware. An association between more advanced CKD stages and higher odds for awareness remained after adjustment for clinical characteristics (Table 2) . Odds for awareness were slightly higher for CKD stages based on eGFR CKD-EPI than for CKD stages based on eGFR MDRD . The association between other clinical characteristics and awareness was not changed substantially when eGFR CKD-EPI was substituted for eGFR MDRD . In participants with eGFR CKD-EPI Ͻ60 mL/min/1.73 m 2 , albuminuria (ACR Ն30 mg/g) was associated with higher odds for aware- Am J Kidney Dis. 2011;57(3)(suppl 2):S17-S23 S19 ness (OR, 1.85; 95% CI, 1.64-2.08) after adjustment for eGFR and other confounders. Although prevalence estimates of awareness changed only modestly, CKD severity classification changed considerably, especially in CKD-unaware participants (Table 3) . Of 23,733 unaware participants with CKD using eGFR MDRD , 2,863 (12.1%) were reclassified to a less advanced CKD stage using eGFR CKD-EPI , including 2,509 (10.6%) who were reclassified to no CKD, and 158 (Ͻ1%) who were reclassified to a more advanced CKD stage. Mean age of unaware participants who were reclassified to no CKD was 55 years, and mean eGFR CKD-EPI was 62 mL/min/1.73 m 2 . All had eGFR MDRD Ն45 mL/min/ 1.73 m 2 ; 77% were women, 72% did not have diabetes, and 80% had hypertension. Of 2,480 aware participants with CKD using eGFR MDRD , 35 (1.4%) were reclassified to a more advanced stage, and 188 (7.5%), to a less advanced stage.
Relative to unchanging CKD stage using eGFR MDRD and eGFR CKD-EPI , reclassification to a less advanced stage using eGFR CKD-EPI was associated with 40% lower odds for CKD awareness (OR, 0.58; 95% CI, 0.50-0.67), and reclassification to a more advanced stage, with 50% higher odds for CKD awareness (OR, 1.50; 95% CI, 1.05-2.13; Table 4 ). These findings persisted after adjustment for age, sex, race, education, and other potential confounders. Results were consistent across all CKD stages, although most pronounced for stages 3-5 using eGFR MDRD (Table 4 ).
DISCUSSION
We found that classification of CKD severity using eGFR CKD-EPI aligned more closely with CKD awareness than classification of severity using eGFR MDRD . Application of eGFR CKD-EPI to KEEP data led to a modest increase in overall awareness rates, primarily due to reclassification of low-risk unaware participants as not having CKD. These findings suggest that eGFR CKD-EPI is a better indicator of the perceived accuracy and prognostic importance of a CKD diagnosis than eGFR MDRD .
Awareness of CKD in the United States is low, especially compared with awareness of chronic conditions associated with CKD, such as hypertension or diabetes, for which awareness rates are Ͼ70%. Providers also must consider the accuracy and prognostic significance of test results and communicate the findings to patients. Concern about provoking anxiety with a potentially inaccurate or inconsequential CKD diagnosis may deter provider communication. 4, 18 Our findings are consistent with this hypothesis. In KEEP, CKD awareness decreased dramatically below stage 4, rather than decreasing stepwise. Furthermore, 10.6% of participants labeled as CKD unaware were reclassified as not having CKD using eGFR CKD-EPI . These participants all had eGFR MDRD of 45-59 mL/min/1.73 m 2 and no albuminuria; most did not have diabetes. Recent findings would suggest that they are a group at lower risk of adverse outcomes. 5, 6, 19 In addition, the cost-effectiveness of early CKD diagnosis has been challenged, primarily due to the potential decrease in quality of life caused by a false-positive diagnosis.
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20, 21 Although the potential effects of a truepositive or false-positive diagnosis cannot be inferred from our findings, they suggest that providers are relying on additional markers of risk beyond eGFR, such as albuminuria or family history, to communicate diagnostic and prognostic information about CKD.
These controversies should not obscure disappointingly low rates of CKD awareness in individuals with eGFR Ͻ30 mL/min/1.73 m 2 , a group for whom CKD awareness is universally considered important for preventing CKD-related complications and prompting preparation for renal replacement therapy. In KEEP, only 39.3% and 59.4% of individuals with eGFR CKD-EPI of 15-30 and Ͻ15 mL/min/1.73 m 2 were aware of CKD, respectively. Correlates of CKD awareness in KEEP were similar to NHANES results; younger patients, men, whites, and patients with hypertension were more likely to be aware of CKD. 3 Curiously, high school education, health insurance, and access to a physician were associated with lower rather than higher odds for awareness, suggesting that poor health literacy and lack of access to care are not major factors preventing awareness. Additional studies are needed to understand the barriers to detection and communication of CKD in this high-risk group.
By showing its relation to CKD awareness, our study also provides indirect evidence of the validity of estimating GFR using the CKD-EPI equation. After the initial validation study, subsequent reports have confirmed that the CKD-EPI equation reduces bias across patient subgroups thought to be at low risk of CKD complications and in those with eGFR Ͼ60 mL/min/1.73 m 2 compared with the MDRD Study equation. 8 Two large cohort studies have noted that eGFR CKD-EPI performs better than eGFR MDRD in predicting risk of death, cardiovascular events, and endstage renal disease. 9, 10 Future studies may be able to determine whether improved accuracy and risk prognostication using eGFR CKD-EPI encourage providers to communicate a diagnosis of CKD more often.
Our study has several limitations common to large studies that use creatinine-based estimating equations for renal filtration function. First, CKD awareness (or lack of) may influence participation in a KEEP screening. Compared with the general US population, KEEP is enriched with individuals at higher risk of CKDrelated morbidity.
22, 23 Second, because we did not have repeated assessments of eGFR, some individuals with acute changes in kidney function may have been misclassified. Finally, the questionnaire item we used to assess awareness may have been misinterpreted by participants, possibly causing underestimates of overall awareness rates. For example, participants may have been told they had "low kidney function" rather than "kidney disease."
In summary, eGFR CKD-EPI more strongly correlated with CKD awareness than eGFR MDRD , and its application to KEEP data led to a modest increase in CKD awareness due to upward reclassification of unaware participants with mild decrements in eGFR. Improvements in GFR estimation, such as with the creatinine-based CKD-EPI equation or other biomarkers of kidney damage, may help increase CKD awareness by reducing provider uncertainty about the accuracy and prognostic significance of a CKD diagnosis.
